UnitedHealthcare sinus surgery policy update — Coverage

Coverage and Medical Necessity Criteria

inv-01: Adult (>=18) Balloon Ostial Dilation and FESS - Chronic Rhinosinusitis

Covered when ALL of the following are met:

Adult CRS coverage: Member age 18 years or older; chronic rhinosinusitis (CRS) duration > 12 weeks; persistence of symptoms despite recent medical management with full courses of appropriate therapy (intranasal corticosteroids ± oral corticosteroids when appropriate; antibiotic therapy if bacterial infection is suspected; nasal lavage/irrigation when appropriate); recent CT scan for each sinus to be treated obtained after completion of medical management documenting which sinus has disease and extent of disease (percent opacification or Modified Lund-Mackay score) with CT findings such as bony thickening, bony remodeling, or opacified sinus and sinonasal symptoms (pain, pressure, or drainage) present on the same side as CT findings; objective evidence of ostial obstruction and mucosal thickening in the sinus to be treated as applicable; and documentation that appropriate conservative medical therapy failed prior to surgical intervention.

Refer to InterQual CP: Procedures, Balloon Ostial Dilation and InterQual criteria for FESS for detailed clinical coverage determination.

inv-02: Pediatric (<18) Balloon Ostial Dilation and FESS - Chronic Rhinosinusitis / RARS

Covered when ALL of the following are met:

Pediatric CRS/RARS coverage: Member age < 18 years; chronic rhinosinusitis (CRS) lasting > 12 weeks OR recurrent acute rhinosinusitis (RARS) defined as ≥ 4 episodes per year with distinct symptom-free intervals; persistence of symptoms despite recent medical management with full courses of appropriate therapy (intranasal corticosteroids ± oral corticosteroids when appropriate; antibiotic therapy if bacterial infection is suspected; nasal lavage/irrigation when appropriate); recent CT images obtained after completion of medical management documenting which sinus has disease and extent of disease (percent opacification or Modified Lund-Mackay score) with CT findings appropriate to the sinus to be treated (for balloon dilation: ostial obstruction and mucosal thickening in the sinus to be dilated; for FESS: ostial obstruction in the sinus to be treated; for maxillary/frontal/sphenoid both mucosal thickening and ostial obstruction; for ethmoid, mucosal thickening required); sinonasal symptoms present on same side as CT findings; and for balloon sinus ostial dilation only, dilation limited to frontal, maxillary, or sphenoid sinuses.

Self-expanding absorptive sinus ostial dilation is considered unproven and not medically necessary.

inv-03: FESS specific indications

FESS is covered when ANY of the following conditions are present:

FESS indications: Complications of sinusitis (such as abscess), symptomatic mucocele, symptomatic concha bullosa, polyposis with obstructive symptoms, sinonasal tumor; OR CRS or RARS that meet the coverage criteria (clinical symptoms plus objective CT or endoscopic findings and failed medical therapy). FESS for the sphenoid sinus is covered when the listed CRS/RARS criteria or CT-confirmed conditions (polyposis with obstruction, mucocele, tumor, or symptomatic disease) are present.

inv-04: Coverage for BSD (selected patients)

Covered when ALL of the following are met

General coverage criteria: Clinical diagnosis of CRS or RARS supported by objective documentation (nasal endoscopy showing sinonasal abnormality or CT demonstrating mucosal thickening/opacification) AND documented failure of appropriate medical therapy (e.g., topical intranasal corticosteroids ± systemic therapy, saline irrigations, antibiotics when indicated) prior to the procedure.

AAO-HNS and specialty guidance support need for objective evidence and failed medical management.

Appropriate patient subsets: Selected patients with limited CRS without polyposis, patients with RARS with CT evidence of ostial occlusion/mucosal thickening, certain frontal sinusitis cases, and patients with persistent disease after prior sinus surgery may be appropriate candidates for balloon sinus ostial dilation (BSD).

Supported by AAO-HNS consensus and primary studies showing benefit in these subgroups.

Setting and adjunct use: BSD may be performed as standalone or adjunct to FESS; choice of setting (office versus operating room) and use as adjunct to other instruments is at surgeon discretion and may influence outcomes in subgroup analyses.

inv-05: Not appropriate uses

Not covered / Not appropriate when ANY of the following apply

No objective disease: Patients without sinonasal symptoms or without positive CT or endoscopic findings (CT does not show evidence of sinonasal disease); balloon dilation is not appropriate in these cases.

AAO-HNS consensus indicates CT scanning of the sinuses is required before balloon dilation.

Headache without CRS: Use of balloon dilation for management of headache (including barometric pressure–related sinus headache) or for apnea in patients who do not otherwise meet CRS or RARS criteria is not appropriate; randomized trials showed no benefit over sham when CT did not demonstrate mucosal thickening.

Laury et al. and other trials demonstrated no advantage in patients without CT evidence of mucosal disease.

inv-06: Indications for balloon ostial dilation or FESS

Covered when ALL of the following are met

Primary coverage criteria: 1) Clinical diagnosis of CRS or RARS based on cardinal symptoms of sinusitis; 2) Objective documentation of sinonasal inflammation by nasal endoscopy or CT demonstrating mucosal thickening or opacified sinuses; 3) Documented failure of appropriate medical therapy (e.g., saline irrigation, topical intranasal corticosteroids, ± systemic antibiotics or adjunctive therapies) prior to surgical intervention; 4) For device-specific interventions or selection (e.g., XprESS), patient selection should be consistent with applicable guidance (typically uncomplicated CRS without severe nasal polyposis).

Supported by AAO-HNS, ARS, ACR and consensus guidance.

inv-07: Imaging requirements

Imaging required when:

Imaging indications: Non-contrast sinus CT is indicated for preoperative planning and objective confirmation when ESS or sinus surgery is being considered (for RARS or CRS); CT provides detailed sinonasal anatomy required to exclude aggressive infection or neoplasm and to delineate ostiomeatal and anatomic variations prior to surgery.CT performed within 12 months recommended

ACR Appropriateness Criteria and AAO-HNS indicators recommend CT imaging after optimal medical therapy when planning surgery.

inv-08: Eligibility for ESS or sinus dilation

Covered when ALL of the following are met

Failed medical therapy: Documented failure of maximal medical therapy (MMT) prior to consideration of ESS or sinus dilation, defined as adequate trials of topical intranasal corticosteroids and adjunctive therapies (e.g., saline irrigations) and systemic antibiotics or anti-inflammatory antibiotic courses when indicated; guideline-recommended minimum trial durations (eg, EUFOREA: ≥8 weeks of topical INS plus systemic course) should be documented.per guideline (example: EUFOREA minimums)

EUFOREA, ICAR-RS, and AAO-HNS guidance describe MMT elements and durations.

Objective evidence of disease: CT imaging demonstrating sinus inflammation/opacification (eg, Lund-Mackay ≥1) and/or endoscopic findings of purulence or inflammation; CT should be obtained when ESS is considered or planned and must identify which sinus has disease and extent of disease.Lund-Mackay ≥1 or equivalent

ICAR-RS and EUFOREA recommend CT and objective findings to support surgery.

inv-09: Insufficient evidence: self-expanding absorptive devices

Experimental/Insufficient evidence for coverage when

Self-expanding absorptive sinus ostial dilation: Standalone use of self-expanding absorptive sinus ostial dilation devices is considered investigational or insufficient evidence for coverage due to small sample sizes and lack of comparative data; available evidence is limited to pilot studies without controls.insufficient evidence

Hathorn et al. (pilot) and other limited reports cited; FDA clearance alone is not a basis for coverage.

inv-10: Medically necessary indications

Covered when ALL of the following are met (examples captured from policy text):

Pediatric CRS criteria: For members under 18 years: CRS lasting >12 weeks AND persistence of symptoms despite recent medical management with full courses of intranasal corticosteroids (± oral corticosteroids when appropriate), antibiotic therapy if bacterial infection is suspected, and nasal lavage/irrigation when appropriate; AND confirmation of CRS on a recent CT scan for each sinus to be treated obtained after medical management documenting percent opacification or equivalent scoring and CT findings such as remodeling, bony thickening, opacified sinus, ostial obstruction, or mucosal thickening; AND sinonasal symptoms (pain, pressure, drainage) present on the same side as CT findings.

Applies to balloon dilation and/or FESS when pediatric criteria are met.

RARS criteria for FESS (including sphenoid): Recurrent acute rhinosinusitis (RARS) defined as ≥ 4 episodes per year with distinct symptom-free intervals AND sinonasal symptoms present on same side as CT findings AND recent CT evidence consistent with required findings (for FESS: for maxillary, frontal, or sphenoid both ostial obstruction and mucosal thickening must be present; for ethmoid, mucosal thickening is required).4+ episodes/year

Policy clarifies FESS for the sphenoid sinus is proven and medically necessary when RARS and CT criteria are met.

Coverage determinations are based on clinical evidence and objective findings, not solely on device marketing or regulatory status. Self-expanding absorptive sinus ostial dilation devices are considered unproven and not medically necessary because available studies are small, noncomparative pilot investigations and do not provide sufficient evidence of safety or effectiveness. (See device-specific pilot data and limitations.)

Functional endoscopic sinus surgery (FESS) and balloon sinus ostial dilation may be considered medically necessary only when the policy’s clinical and imaging criteria are met and when appropriate medical management has failed; FDA clearance or device listing alone is provided for informational purposes and is not a basis for coverage.

Balloon sinus ostial dilation is not appropriate for patients who do not have both sinonasal symptoms and objective imaging or endoscopic evidence of disease. CT scanning of the sinuses is required prior to balloon dilation, and the procedure should not be used to treat isolated headache or apnea when CT does not show mucosal thickening or ostial obstruction.

Randomized and controlled evidence evaluating balloon dilation for barometric-pressure or rhinogenic headache in patients without CT evidence of mucosal disease has not shown benefit over placebo, supporting the exclusion of patients lacking both symptoms and positive CT findings from coverage.

Patients with severe nasal polyposis are not the preferred population for some device-based dilation systems; NICE assessed the XprESS multi‑sinus dilation system and recommended it for patients with uncomplicated CRS who do not have severe nasal polyposis. Device-specific guidance therefore limits balloon-based approaches in the presence of significant polyposis.

When polyposis or other anatomic disease (e.g., tumor, mucocele) is present and is the primary driver of obstruction, FESS or other standard surgical approaches are the preferred, proven interventions rather than balloon-only dilation.

Information about FDA device classification or 510(k) clearance is provided for context but is not determinative for coverage. The FDA classifies many ENT manual surgical instruments, including dilation devices, under product code LRC and some devices have received 510(k) clearance; however, FDA clearance or device listing alone is not a basis for medical necessity or coverage

FESS is a surgical procedure and therefore is not subject to FDA approval; devices used during FESS may have separate regulatory statuses that are informational only.

Balloon sinus ostial dilation and self-expanding absorptive sinus ostial dilation are considered unproven and not medically necessary for treating sinonasal polyps or tumors, and for cases of CRS or RARS that do not meet the policy’s specified clinical and imaging criteria due to insufficient evidence of efficacy.

Self-expanding absorptive devices in particular lack comparative data and consist mainly of small pilot studies; their standalone use for evaluation or treatment of sinusitis is therefore excluded from coverage.

Balloon sinus ostial dilation and FESS are not medically necessary when the case of chronic rhinosinusitis (CRS) or recurrent acute rhinosinusitis (RARS) does not meet the policy’s clinical, medical management, and imaging criteria. Documentation must support persistent symptoms after appropriate medical therapy and objective disease on CT or endoscopy.

Standalone use of self-expanding absorptive sinus ostial dilation devices is considered investigational/unsupported by sufficient evidence and is therefore not medically necessary for any indication at this time.

Balloon sinus ostial dilation is not appropriate for the treatment of barometric pressure–related sinus headache in patients without CT evidence of mucosal thickening. A randomized single-blinded RCT that enrolled patients without CT mucosal disease found no advantage of active balloon dilation over placebo nasal dilation for headache outcomes.

Requests for balloon dilation for isolated headache symptoms without objective sinonasal disease should be denied as not medically necessary.

The use of balloon dilation as a general substitute for FESS in patients with greater disease burden (extensive polyposis, diffuse mucosal disease, or other anatomic disease requiring tissue removal) is unproven. There is insufficient evidence that balloon-only approaches provide equivalent long‑term outcomes compared with FESS when a higher disease burden exists, and therefore substituting balloon dilation for appropriately indicated FESS is not supported.

Patient selection should follow guideline recommendations that reserve balloon ostial dilation primarily for limited disease, RARS with ostial occlusion, or adjunctive use rather than as a universal replacement for standard surgical techniques.

Standalone self-expanding absorptive sinus ostial dilation devices are considered investigational or insufficiently supported for coverage. Existing evidence is limited to pilot series without control groups and small sample sizes, so safety and comparative effectiveness remain uncertain.

Functional endoscopic sinus surgery (FESS) is a proven surgical technique for appropriately selected patients, but it is not medically necessary when the CRS or RARS case does not meet the policy’s clinical and imaging criteria. FESS is indicated for complications confirmed on CT (abscess, symptomatic mucocele, symptomatic concha bullosa, polyposis with obstructive symptoms, sinonasal tumor) and for CRS/RARS that meet medical therapy failure and objective disease requirements; otherwise it should not be performed for routine cases lacking those criteria.

As with balloon dilation, FESS should be supported by documentation of failed medical therapy and objective CT or endoscopic findings before authorization.

Procedure Codes, Key Thresholds, and Coding Notes

Applicable Procedure CPT CodesCPT

31240	Nasal/sinus endoscopy, surgical; with concha bullosa resection.
31253	Nasal/sinus endoscopy, surgical with ethmoidectomy; total (anterior and posterior), including frontal sinus exploration, with removal of tissue from frontal sinus, when performed.
31254	Nasal/sinus endoscopy, surgical with ethmoidectomy; partial (anterior).
31255	Nasal/sinus endoscopy, surgical with ethmoidectomy; total (anterior and posterior).
31256	Nasal/sinus endoscopy, surgical, with maxillary antrostomy.
31257	Nasal/sinus endoscopy, surgical with ethmoidectomy; total (anterior and posterior), including sphenoidotomy.
31259	Nasal/sinus endoscopy, surgical with ethmoidectomy; total (anterior and posterior), including sphenoidotomy, with removal of tissue from the sphenoid sinus.
31267	Nasal/sinus endoscopy, surgical, with maxillary antrostomy; with removal of tissue from maxillary sinus.
31276	Nasal/sinus endoscopy, surgical, with frontal sinus exploration, including removal of tissue from frontal sinus, when performed.
31287	Nasal/sinus endoscopy, surgical, with sphenoidotomy.

1–10 of 16
1/2

Device-specific referencemixed

XprESS (device)

NICE guidance referenced for XprESS multi sinus dilation system

FDA product codes for ENT devicesmixed

LRC	FDA product code category for ENT manual surgical instruments (includes dilation devices)

References (no billing codes in this section)mixed

No codes listed

inv-25: Recent CT timeframe — CT performed within 12 months

Recent CT timeframeCT performed within 12 months of the planned procedure

CT timing requirementCT images must be obtained after completion of medical management for the sinus(es) to be treated

Purpose of recent CTProvide objective evidence of mucosal thickening/opacification, ostial obstruction, remodeling or bony thickening for surgical planning

inv-26: CRS duration threshold — >= 12 weeks

CRS duration threshold>= 12 weeks (inflammatory process persisting longer than 12 weeks)

Symptom requirement

Prior Authorization, Documentation, and Denial Triggers

Prior Authorization
Prior Authorization Required
Prior authorization is required per plan rules for requests for balloon sinus ostial dilation or Functional Endoscopic Sinus Surgery (FESS). Prior authorization requests must document objective findings confirming sinonasal disease and evidence that the member has failed appropriate medical therapy prior to surgery.
Prior authorization applies to listed CPT procedure codes for sinus procedures (see Applicable Codes).
Requests for BSD or FESS without objective documentation (endoscopy or CT) or without evidence of failed medical therapy are at risk for denial.

Documentation Required
Required Clinical and Objective Documentation
Document the clinical diagnosis and include supporting objective findings and imaging. Objective documentation must include either nasal endoscopy demonstrating sinonasal inflammation/purulence or a recent non-contrast sinus CT demonstrating mucosal thickening, ostial obstruction, opacification, bony remodeling/thickening, or percent opacification (Modified Lund-Mackay or similar). CT considered recent when performed within 12 months of planned procedure.

Key Definitions and Terms

Chronic rhinosinusitis (CRS) is an inflammatory process of the paranasal sinuses that persists for more than 12 weeks and requires both symptoms (e.g., nasal obstruction, mucopurulent drainage, facial pain/pressure, or decreased sense of smell) and objective evidence of inflammation (nasal polyps, mucosal edema, purulence, or radiographic imaging).

Diagnostic confirmation for surgical consideration should include documentation of symptom duration, response (or lack of response) to maximal medical therapy, and objective findings such as endoscopic purulence or mucosal thickening on CT.

inv-54: Chronic Rhinosinusitis (CRS) — definition and symptom criteria

Definition of CRSInflammation of the paranasal sinuses persisting longer than 12 weeks with two or more symptoms (nasal obstruction, mucopurulent drainage, facial pain/pressure, decreased sense of smell)

Inflammation documentationRequires documentation of inflammation by polyps, edema, purulent mucus, or radiographic imaging

Symptom and objective correlationDiagnosis requires persistent symptoms plus objective findings (endoscopy or CT) demonstrating sinonasal inflammation

Background, Evidence Summary, and Clinical Context

CRS management includes guideline-recommended medical therapies (saline irrigation, topical intranasal corticosteroids, and, when indicated, systemic antibiotics or corticosteroids). Balloon sinus ostial dilation (balloon sinuplasty) is a technique that dilates obstructed sinus ostia (frontal, maxillary, sphenoid) and may be used as a standalone procedure or adjunct to FESS in selected patients after failure of medical therapy.

Self-expanding absorptive devices have been proposed as an alternative to standard balloon dilation but remain under investigation; current evidence does not support routine clinical use.

Policy Changes and Revision History

2025-09-01policy_effective_dateLatest

Policy revision effective: updated coverage rationale for members 18 years and older; clarified FESS indication for sphenoid sinus and added pediatric-specific criteria for balloon ostial dilation and FESS.

2025-09revision_entry

Documentation requirements clarified to identify which sinus has disease and the extent of disease (percent opacification or modified scoring) and to require recent CT images obtained after completion of medical management.

2016-12

OpenPayer

Sinus Surgeries and Interventions (for Kansas Only)

Coverage and Medical Necessity Criteria

Procedure Codes, Key Thresholds, and Coding Notes

Prior Authorization, Documentation, and Denial Triggers

Key Definitions and Terms

Background, Evidence Summary, and Clinical Context

Policy Changes and Revision History